ArunA Bio was the first to commercialize human neural stem cells derived from human pluripotent stem cells.

For over twelve years, we manufactured and provided neural stem cells to the world’s leading research organizations with unrivaled uniformity and scale.

Today, we are advancing a new class of cell-free biologics, exosomes, for the treatment of central nervous system (CNS) and neurodegenerative disorders and leveraging our novel platform to optimize the delivery of RNAs, antibodies, genes and small molecules for our partners.

Through this platform and our partners, we strive to improve outcomes for CNS cancers, neurodegenerative, genetic and rare diseases.

To date, our exosomes have demonstrated the ability to:

  • Be safely administered intravenously in multiple doses with no adverse side effects

  • Cross the blood-brain barrier non-invasively to reach the site of injury

  • Reduce inflammation and enhance neural function

  • Improve motor function and behavioral outcomes

To learn more about the therapeutic potential of our exosomes and our program in stroke, click here.

To learn how exosomes can solve your drug delivery problems, click here.